House bill would speed approval once EU OKs same product

Share this article:
House bill would speed approval once EU OKs same product
From left: Rep. Steve Stivers (R-OH) and Rep. Tim Ryan (D-OH)

Rep. Steve Stivers (R-OH) has introduced the Speeding Access to Already Approved Pharmaceuticals Act of 2014, which would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union (EU). The bill is cosponsored by Rep. Tim Ryan (D-OH).

“Unfortunately, the United States FDA's red tape causes delays of up to several years in approval for life-saving and life-changing medical treatments,” Stivers says in a statement.

“These delays result in unnecessary death and suffering of American patients. This bill will help speed U.S. approval of drugs and medical devices deemed safe and effective by European Authorities. It ensures the safety of these drugs while saving lives and improving the quality of life for millions of Americans who need cutting-edge medical treatments.”

Specifically, the bill would require FDA to facilitate the development and expedite the review of a drug within 90 days after the EU approves a pharmaceutical product.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...